Clinical Trial Update: Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI [NA]

View source ↗

Summary

An update on a clinical trial of riboflavin corneal crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type 6; the trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brittle Cornea Syndrome
• Ehlers-danlos Syndrome Type 6

Drugs mentioned

• Riboflavin Corneal Crosslinking

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Brittle Cornea Syndrome, Ehlers-Danlos Syndrome Type 6 | NA | Status: UNKNOWN